Claims for Patent: 8,623,606

Summary for Patent: 8,623,606

Title:	Screening method for GPCR ligands
Abstract:	This invention relates to a method of identifying a compound capable of binding to a target domain of a G-protein coupled receptor comprising the steps of: (a) providing a receptor comprising said target domain and a first group linked to said target domain; (b) bringing into contact said receptor of (a) with a test molecule comprising a second group and said compound linked to each other, wherein said first group binds said second group; and (c) determining, subsequent to the binding of said first group to said second group, whether said compound binds to said target domain.
Inventor(s):	Hausch; Felix (Munchen, DE), Perez-Balderas; Francisco (Oxford, GB)
Assignee:	Max-Planck-Gesellschaft zur Forderung der wissenschaften E.V. (Munich, DE)
Application Number:	12/310,296
Patent Claims:	1. A method of identifying a compound capable of forming a weak bond with a target domain of a G-protein coupled receptor comprising the steps of: (a) providing a receptor comprising said target domain and a first group linked to said target domain, wherein said target domain comprises the transmembrane or juxtamembrane domain of said G-protein coupled receptor, and wherein said first group comprises: (i) the N-terminal domain of said G-protein coupled receptor; (ii) the N-terminal domain of a different G-protein coupled receptor fragment or analog thereof; or (iii) avidin or biotin; a metal ion or chelator; a strep-tag or strep-tactin; glutathion or GST; tetracystein or diarsen; (b) bringing into contact said receptor of (a) with a test molecule comprising a second group and said compound linked to each other, wherein said first group binds said second group, wherein said second group comprises a component selected from the group consisting of (i) the C-terminal part of a natural cognate ligand of said G-protein coupled receptor defined in (a) (i) or (ii) capable of binding said N-terminal domain defined in (a) (i) or (ii); and (ii) biotin or avidin; a metal ion or chelator; a strep-tag or strep-tactin; glutathion or GST; tetracystein or diarsen; and (c) determining, subsequent to the binding of said first group to said second group, whether said compound forms a weak bond to said target domain, and wherein said compound is a peptide, peptidomimetic or small organic molecule, thereby identifying a compound capable of forming a weak bond with a target domain of a G-protein coupled receptor. 2. The method of claim 1, wherein said first group is linked to at least one of the N-Terminus of said transmembrane domain, the N-terminus of said juxtamembrane domain. 3. The method of claim 1, wherein said G-protein coupled receptor is a class B G-protein coupled receptor. 4. The method of claim 3, wherein said class B G-protein coupled receptor is selected from the group consisting of corticotropin releasing factor receptors CRFR1, CRFR2a, CRFR2b and CRFR2c; parathyroid hormone receptors PTHR1 and PTHR2; glucagon receptor; growth hormone releasing hormone receptor; glucagon-related peptide receptors GLP 1 R and GLP2R; gastric inhibitory polypeptide receptor; secretin receptor; calcitonin receptor; calcitonin receptor-like receptor; vasoactive intestinal peptide receptors VIPR1 and VIPR2; and adenylate cyclase activating polypeptide 1 receptor. 5. The method of claim 1, wherein said compound is selected from the group consisting of a peptide, a peptidomimetic and a small organic molecule. 6. The method of claim 1, wherein said compound has a molecular weight below 300 Da. 7. The method of claim 1, wherein said receptor is selected from the group consisting of (i) solubilized; and (ii) located in a membrane of a micelle or a membrane preparation. 8. The method of claim 1, wherein said target domain and said first group, and/or wherein said second group and said compound are linked through a linker, said linker is selected from the group consisting of alkyl with 1 to 30 carbon atoms, polyethylene glycol with 1 to 20 ethylene moieties, polyalanine with 1 to 20 residues, caproic acid, substituted or unsubstituted poly-p-phenylene and triazol.

Details for Patent 8,623,606

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Nps Pharmaceuticals, Inc.	NATPARA	parathyroid hormone	For Injection	125511	01/23/2015		2026-08-22